Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...
The phase 4, open-label AGILE trial compared the safety and efficacy of 60-, 45-, and 30-minute pegloticase infusions vs standard 120-minute protocols.
Inova optimized infusion operations using AI to improve scheduling, expand access, and enhance the patient experience in Northern Virginia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback